FERM and PDZ domain containing 2B (pseudogene)Genealiases: []
Q-omics provides the consensus-scored FRMPD2B profile across patient tissues and cancer cell-line models. FRMPD2B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, FRMPD2B is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, FRMPD2B RNA expression shows 8,758 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight DLBC, LUAD, and GBM as cancer lineages where FRMPD2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRMPD2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRMPD2B survival associations across molecular data types. FRMPD2B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRMPD2B RNA expression–survival associations across cancer types. High FRMPD2B expression shows unfavorable associations in DLBC and TGCT, but favorable associations in BLCA, UCEC, KIRC and LUAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for FRMPD2B RNA expression.
This table summarizes FRMPD2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FRMPD2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRMPD2B shows lower tumor expression in LUAD, LUSC, BRCA and KICH and higher tumor expression in LIHC. The LUAD box plot shows higher FRMPD2B RNA expression in normal versus tumor tissue (log2 FC = −0.221, t-test p = .001).
This table shows molecular features associated with FRMPD2B in patient tissues and cancer cell lines. In patient samples, FRMPD2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRMPD2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
